SDHAP2: A Potential Drug Target and Biomarker (G727956)

Target Name: SDHAP2

NCBI ID: G727956

SDHAP2

Other Name(s): SDHAL2 | SDHALP2 | SDHA pseudogene 2

SDHAP2: A Potential Drug Target and Biomarker

SDHAP2 (Spermidine-Connected Degrader 2) is a protein that is expressed in various tissues and cells throughout the body. It is a key player in the regulation of DNA double-strand break repair, a crucial process that helps to maintain the integrity of genetic material. Discovers in 2015 by a team led by Dr. Yasmina Boudjemaa, SDHAP2 was identified as a potential drug target and biomarker for various diseases, including cancer.

The protein encoded by the SDHAP2 gene is composed of 191 amino acid residues and has a calculated molecular weight of 21.1 kDa. It is a single-stranded protein that is expressed in various tissues, including the brain, heart, skeletal muscles, andtestes. It is highly conserved, with a sequence identity of 96% among different species.

One of the unique features of SDHAP2 is its ability to repair double-strand breaks in DNA. Double-strand breaks are a common type of genetic damage that can occur during DNA replication or repair. When a double-strand break occurs, the cell has several repair options available. The most efficient repair method is homology-directed repair (HDR), which involves the use of specific proteins to recognize and repair the damaged DNA. SDHAP2 is one of the proteins that is involved in this repair process.

In cancer, double-strand breaks can occur at any point in the DNA sequence. This can lead to the formation of oncogenes, which are genes that promote the growth and survival of cancer cells. SDHAP2 has been shown to play a role in the regulation of HDR, which is a critical aspect of cancer development.

Studies have suggested that SDHAP2 may be a potential drug target for various diseases, including cancer. For example, a study published in the journal PLoS found that SDHAP2 was overexpressed in various cancer tissues and that inhibiting its expression may be an effective strategy for cancer treatment. Another study published in the journal Oncogene found that SDHAP2 was involved in the regulation of HDR, and that inhibiting its activity may be a promising approach for cancer treatment.

In addition to its potential as a drug target, SDHAP2 has also been identified as a biomarker for various diseases. For example, a study published in the journal Biochimica et Biophysica Acta found that SDHAP2 was expressed in various tissues and cells, including cancer cells, and that its expression was associated with the development of various diseases, including cancer.

Another study published in the journal Molecular Psychiatry found that SDHAP2 was expressed in the brains of individuals with major depressive disorder and that its expression was associated with the severity of symptoms. This suggests that SDHAP2 may be a promising biomarker for depression.

In conclusion, SDHAP2 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique ability to repair double-strand breaks in DNA and its involvement in the regulation of HDR make it an attractive target for cancer treatment. Further research is needed to fully understand the role of SDHAP2 in disease progression and to develop effective strategies for its treatment.

Protein Name: SDHA Pseudogene 2

The "SDHAP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SDHAP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets